Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas

Cancer Res. 2003 Oct 1;63(19):6195-9.

Abstract

Overexpression of cdc25B, an important cell cycle regulator, has been shown to result in mammary gland hyperplasia in transgenic mice and to increase steroid hormone responsiveness as a direct coactivator of the estrogen receptor (ER). We investigated the potential role of cdc25B in the pathogenesis of endometrial carcinomas in conjunction with ER-alpha. We examined the expression of cdc25B and phosphorylated ER-alpha in 4 archived human specimens of normal endometrium; 7 endometrial hyperplasia with or without atypia; 32 endometrioid endometrial carcinoma (EEC), including 20 low-grade (grade 1) and 12 high-grade (grade 2 or 3) tumors; and 18 endometrial cancers with aggressive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by immunohistochemistry with monoclonal antibodies. Expression of cdc25B and phosphorylated ER-alpha was increased in endometrial hyperplasia and atypical hyperplasia compared with normal secretory endometrium. Ninety percent (18 of 20) of the low-grade EEC expressed cdc25B at a high level, whereas only 42% (5 of 12) of the high-grade EEC did so (chi(2) = 8.7; P < 0.01). Sixty-five percent (13 of 20) of the low-grade EEC expressed phosphorylated ER-alpha at high levels, but only 17% (2 of 12) of high-grade EEC did so (chi(2) = 7.0; P < 0.01). Coordinate high-level expression of phosphorylated ER-alpha and cdc25B occurred in 65% (13 of 20) of low-grade EEC but in only 17% (2 of 12) of the high-grade EEC (chi(2) = 7.0; P < 0.01). In the UPSC/CCC tumors, only 22% (4 of 18) of the tumors expressed phosphorylated ER-alpha at high-levels. However, 83% (15 of 18) of these carcinomas showed high expression of cdc25B (chi(2) = 13.5; P < 0.01). The majority of the UPSC/CCC (15 of 18) did not show coordinate high expression of phosphorylated ER-alpha and cdc25B. Our findings show that in endometrial hyperplasia and low-grade EEC, coordinate increase in cdc25B and phosphorylated ER-alpha occurs. However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-alpha. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms.

MeSH terms

  • Adenocarcinoma, Clear Cell / metabolism
  • Adenocarcinoma, Clear Cell / pathology
  • Carcinoma, Endometrioid / metabolism*
  • Carcinoma, Endometrioid / pathology*
  • Carcinoma, Papillary / metabolism
  • Carcinoma, Papillary / pathology
  • Cell Cycle Proteins / biosynthesis*
  • Cystadenocarcinoma, Papillary / metabolism
  • Cystadenocarcinoma, Papillary / pathology
  • Cystadenocarcinoma, Serous / metabolism
  • Cystadenocarcinoma, Serous / pathology
  • Endometrial Neoplasms / metabolism*
  • Endometrial Neoplasms / pathology*
  • Estrogen Receptor alpha
  • Female
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Neoplasm Proteins / biosynthesis
  • Phosphorylation
  • Receptors, Estrogen / biosynthesis*
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / biosynthesis
  • Uterine Neoplasms / metabolism
  • Uterine Neoplasms / pathology
  • cdc25 Phosphatases / biosynthesis*

Substances

  • Cell Cycle Proteins
  • Estrogen Receptor alpha
  • Neoplasm Proteins
  • Receptors, Estrogen
  • Receptors, Progesterone
  • estrogen regulated protein
  • CDC25B protein, human
  • cdc25 Phosphatases